There are currently 167 active clinical trials seeking participants for Lung Cancer research studies. The states with the highest number of trials for Lung Cancer participants are Ohio, California, Illinois and Michigan.
Evaluation for NCI Surgery Branch Clinical Research Protocols
NCT00001823
Recruiting
Background: The National Cancer Institute Surgery Branch (NCI-SB) has developed experimental therapies that involve taking white blood cells from patients' tumor or from their blood, growing them in the laboratory in large numbers, and then giving the cells back to the patient. Objective: This study will allow patients to under screening and evaluation for participation in NC-SB Protocols. Eligibility: Patients 18 years or older must meet the minimum eligibility criteria for an NCI-SB treat... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Synovial Cell Cancer, Melanoma, Colorectal Cancer, Lung Cancer, Bladder Cancer
Register for Updates
Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies
NCT00451022
Recruiting
This study aims to provide long-term follow-up care of patients previously enrolled in a vaccine study that involved poxviral vectors. Vectors are sequences of genetic material that can be used to introduce specific genes into genetic makeup. The study does not involve the use of any drug or biologic agent. Participants will undergo an annual health history. Because certain viruses enter into cells and create proteins from the viral genes, the type of vaccine treatment used is referred to gene t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Prostate Cancer, Liver Cancer, Breast Cancer, Colon Cancer, Lung Cancer
Register for Updates
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
NCT06685718
Recruiting
This is an open-label, multicenter, Phase 1a/1b clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BG-60366, a highly potent, selective EGFR-mutation targeted Chimeric Degradation Activation Compound (CDAC). BG-60366 is designed to degrade mutant EGFR, which is a common cause for Non-Small Cell Lung Cancer (NSCLC). This study will evaluate how well BG-60366 works in participants with advanced or metastatic EGFR-mutant NS... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: University of Colorado, Denver, Colorado +38 locations
Conditions: Non-Small Cell Lung Cancer, Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma), EGFR Activating Mutation, EGFR Mutation-Related Tumors
Register for Updates
Exercise as Maintenance Therapy in Advanced Lung Cancer
NCT06513663
Recruiting
The purpose of this study is to examine how a multimodality (having or using a variety of methods to do something) exercise intervention may improve survival, function, and quality of life in participants with advanced lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/29/2025
Locations: Indiana University Health Methodist Hospital, Indianapolis, Indiana +2 locations
Conditions: Lung Cancer, Non Small Cell Lung Cancer, Metastatic Lung Cancer
Register for Updates
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
NCT06618287
Recruiting
The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: Local Institution - 0009, Miami, Florida +44 locations
Conditions: Lung Cancer
Register for Updates
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
NCT06778863
Recruiting
Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A\*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: USC - Norris Comprehensive Cancer Center, Los Angeles, California +4 locations
Conditions: Advanced Solid Tumor, Unresectable Solid Tumor, Metastatic Solid Tumor, Colorectal Adenocarcinoma, Pancreatic Adenocarcinoma, Lung Cancer, Ovarian Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Bladder Cancer
Register for Updates
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
NCT04585750
Recruiting
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, tolerability and preliminary efficacy of multiple dose levels of rezatapopt as monotherapy and in Phase 1b in combination with pembrolizumab.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
04/24/2025
Locations: Hoag Cancer Center, Irvine, California +73 locations
Conditions: Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer
Register for Updates
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
NCT06698042
Recruiting
Researchers are looking for new ways to treat non-small cell lung cancer (NSCLC) that is metastatic, which means cancer has spread to other parts of the body. Some people with metastatic NSCLC are treated with pembrolizumab, an immunotherapy treatment that is given into a vein as an intravenous (IV) infusion. Pembrolizumab (+) Berahyaluronidase alfa is pembrolizumab that is given under the skin as a subcutaneous (SC) injection. The goal of this study is to compare what happens to pembrolizumab... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: Illinois Cancer Care ( Site 0101), Peoria, Illinois +50 locations
Conditions: Lung Cancer, Non-Small Cell Lung Cancer
Register for Updates
Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements
NCT05987644
Recruiting
This study will consist of a Phase 1b and Phase 2 portion. The Phase 1b portion will enroll first followed by the Phase 2 portion. Each cycle of treatment = 28 days. Subjects will receive alectinib twice daily. Those in the Phase 1b portion will receive alectinib alone. Those in Phase 2 Arm A will receive alectinib alone. Those in Phase 2, Arm B will receive SRS + alectinib. A maximum of 25 cycles (2 years) of alectinib may be administered on study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: Stanford University, Stanford, California +1 locations
Conditions: Lung Cancer, NSCLC, Brain Metastases
Register for Updates
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
NCT06060613
Recruiting
This is a study to investigate the safety and efficacy of an investigational OBX-115 regimen in adult participants with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/23/2025
Locations: The Angeles Clinic and Research Institute (Melanoma), Los Angeles, California +8 locations
Conditions: Tumor Skin, Metastatic Melanoma, Melanoma, Lung Cancer, Metastatic Lung Cancer, Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
Register for Updates
Prospective Evaluation of the Tool-in-lesion Technology of the Galaxy System in Routine Clinical Practice
NCT06685133
Recruiting
A prospective observational study evaluating the accuracy of the tool-in-lesion technology of the Galaxy SystemTM in normal clinical practice.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/22/2025
Locations: CHI Memorial Hospital, Chattanooga, Tennessee +1 locations
Conditions: Lung Cancer, Lung; Nodule
Register for Updates
A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation
NCT05118854
Recruiting
This is a phase II, single-arm, open-label study evaluating the efficacy, safety and tolerability of neoadjuvant sotorasib in combination with cisplatin (or carboplatin) and pemetrexed chemotherapy for patients with surgically resectable stage IIA - IIIB (T3-T4/N2) (based on AJCC 8th edition), non-squamous NSCLC with a KRAS p.G12C mutation. The primary objective of the study is to determine whether neoadjuvant therapy with 4 cycles of at least one dose of sotorasib plus cisplatin (or carboplatin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/22/2025
Locations: Memorial Sloan Kettering Cancer Center, New York, New York +1 locations
Conditions: Lung Cancer
Register for Updates